Zur Kurzanzeige

dc.contributor.advisorSchmitz, Lienhard
dc.contributor.advisorWeber, Friedemann
dc.contributor.advisorBauer, Stefan
dc.contributor.advisorFinke, Stefan
dc.contributor.authorPanagiotidis, Georgios Dimitrios
dc.date.accessioned2023-03-20T07:29:55Z
dc.date.available2023-03-20T07:29:55Z
dc.date.issued2022
dc.identifier.urihttps://jlupub.ub.uni-giessen.de//handle/jlupub/12009
dc.identifier.urihttp://dx.doi.org/10.22029/jlupub-11392
dc.description.abstractHuman viral respiratory pathogens influenza A virus (FLUAV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS–CoV–2) are a significant burden on human health. Even though antivirals are available, the infection numbers still remain significant. Recent in silico data provided insight on potential inhibitors against these viruses. One of the top hits was the schizophrenia drug Paliperidone which was predicted to disrupt the interaction of FLUAV polymerase subunit PB2 with the nucleoprotein NP and to inhibit SARS–CoV–2 protease 3CLpro. In this work the effect and mechanism of action of Paliperidone against FLUAV and effect on SARS–CoV–2 were to be determined. Paliperidone exhibited early inhibitory effect against A/PR/8/34 in RNA, protein and titer levels with the latter observed, in human airway bronchial cell system. Furthermore, Paliperidone exhibited mild inhibitory effect against other H1N1 strains in RNA, protein and viral polymerase levels, failing to affect strain A/WSN/33 PB2 627E (avian) whatsoever. In this study, was, also, in vitro proved, that Paliperidone disrupts the interaction of PB2 and NP of A/PR/8/34. Paliperidone was also found, here, to inhibit SARS–CoV–2 only on RNA levels. All these indicate that Paliperidone might represent a compound of interest for further development of FLUAV and SARS–CoV–2 antivirals. RIG–I is an innate immune cytosolic pattern recognition receptor inducing type 1 interferon response and senses RNA of FLUAV and SARS–CoV–2. RIG–I domains CARDs and helicase are indispensable for interferon response. Studies with signalling deficient RIG–I, indicated that it has direct antiviral effect against FLUAV. Thus, in this study, a set of mutations on RIG–I that affect signalling were inhibitory against A/PR/8/34 in RNA levels in kidney cells. Furthermore, in adenocarcinoma alveolar cells, the signalling deficient RIG–I DC (ΔCARD) exhibited inhibitory effect against only strain A/PR/8/34 on RNA levels, failing to affect strain A/WSN/33 PB2 627E (avian) and SARS–CoV–2. These indicate that, signalling deficient RIG–I is of interest to study for its direct antiviral activity against FLUAV.de_DE
dc.description.sponsorshipDeutsche Forschungsgemeinschaft (DFG); ROR-ID:018mejw64de_DE
dc.language.isoende_DE
dc.rightsIn Copyright*
dc.rights.urihttp://rightsstatements.org/page/InC/1.0/*
dc.subjectVirologyde_DE
dc.subjectImmunologyde_DE
dc.subjectPaliperidonede_DE
dc.subject.ddcddc:570de_DE
dc.titleAntiviral intervention strategies against RNA viruses: Roles of Paliperidone and RIG–Ide_DE
dc.typedoctoralThesisde_DE
dcterms.dateAccepted2023-03-01
local.affiliationFB 11 - Medizinde_DE
local.projectKFO309 P1de_DE
thesis.levelthesis.doctoralde_DE


Dateien zu dieser Ressource

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige

Urheberrechtlich geschützt